UPMC is partnering with a clinical diagnostics company to see how proteomics could be used to impact clinical care.
Under the collaboration, the Pittsburgh-based provider will use SomaLogic's clinical research platform and development projects to see how proteomic data can potentially be used to, for instance, inform doctors and patients as to a person's real-time health status or disease risk.
"We are evaluating whether a proteomics approach can help clinicians identify patients at the highest risk for major health events, like heart attack or stroke," Suresh Mulukutla, an interventional cardiologist at UPMC and director of analytics for the UPMC Heart and Vascular Institute, said in a statement. "That will allow us to better target interventions and care."
"UPMC is committed to supporting innovative healthcare technologies with the goal of providing life-changing medicine to our patients and communities," said Matthias Kleinz, senior VP and head of translational sciences at UPMC Enterprises.
Boulder, Colorado-based SomaLogic uses an aptamer-based affinity reagent to measure proteins in patient samples, typically in blood.
This month the company listed on the Nasdaq after completing a business combination with special purpose acquisition company CM Life Sciences II that raised $630 million in gross proceeds.
This story first appeared in our sister publication, Genomeweb.
